Botella A, Rekik M, Delvaux M, Davicco M J, Barlet J P, Frexinos J, Bueno L
Department of Pharmacology, Institut National de Recherche Agronomique, Toulouse, France.
Endocrinology. 1994 Nov;135(5):2160-7. doi: 10.1210/endo.135.5.7525262.
PTH-related peptide (PTHrP), which shares 8 of 13 NH2-terminal residues with PTH, causes similar biological effects and interacts with the same receptor as PTH. In the gastrointestinal tract, human PTH and PTHrP-(1-34) relax rat fundic strips. However, the level of their action and the receptor involved in this effect are unknown. The aims of this study were 1) to determine the effects of human PTH-(1-34), human PTHrP-(1-34), -(1-16), and -(7-34) and vasoactive intestinal peptide (VIP) on circular isolated smooth muscle cells from guinea pig ileum; 2) to study the intracellular pathways involved in these effects; and 3) and to characterize the receptors involved by using specific antagonists. Smooth muscle cells were dispersed by enzymatic digestion. Contraction was assessed by measuring the length of 50 cells and expressed as the percent decrease in cell length from the control value. The relaxing effects of PTH, PTHrP and analogs, VIP, or antagonists were expressed as a percentage of the maximal effect observed in their absence. VIP, PTH-(1-34), and PTHrP-(1-34), -(1-16), and -(7-34) had no effect by themselves on these cells. However, when cells were contracted by the sulfated C-terminal octapeptide of cholecystokinin (10 nM), VIP, PTH-(1-34), and PTHrP(1-34) inhibited the sulfated C-terminal octapeptide of cholecystokinin-induced contraction in a concentration-dependent manner, whereas PTHrP-(1-16) and -(7-34) had no effect. The EC50 values of VIP, PTH-(1-34), and PTH-(1-34), and PTHrP-(1-34) were 7 nM, 20 pM, and 20 pM, respectively. The VIP antagonist ([D-P-Cl-Phe6,Leu17]VIP) inhibited VIP-, PTH-(1-34)-, and PTHrP(1-34)-induced relaxation, with IC50 values of 20, 500, and 400 pM, respectively. Likewise, the PTH/PTHrP antagonist [Tyr34-bovine PTH-(7-34)NH2] inhibited PTH-(1-34)-, PTHrP(1-34)-, and VIP-induced relaxation, with IC50 values of 1, 1, and 90 pM, respectively. Preincubation of cells with somatostatin, N-ethylmaleimide, and (R)-p-cyclic adenosine-3',5'-monophosphothioate inhibited the PTH-(1-34), PTHrP(1-34)-, and VIP-induced relaxation. In conclusion, human PTH and PTHrP induce a relaxation of intestinal smooth muscle by a direct myogenic effect. This effect requires the 1-34 amino acid sequence and is mediated by the activation of adenylate cyclase and protein kinase-A. Interactions among PTH, PTHrP, and VIP indicate that they may cross-react with their respective receptors.
甲状旁腺激素相关肽(PTHrP)与甲状旁腺激素(PTH)在13个氨基末端残基中有8个相同,具有相似的生物学效应,并与PTH作用于相同的受体。在胃肠道中,人PTH和PTHrP-(1-34)可使大鼠胃底条松弛。然而,它们的作用水平以及参与此效应的受体尚不清楚。本研究的目的是:1)确定人PTH-(1-34)、人PTHrP-(1-34)、-(1-16)和-(7-34)以及血管活性肠肽(VIP)对豚鼠回肠环形分离平滑肌细胞的影响;2)研究这些效应所涉及的细胞内途径;3)使用特异性拮抗剂对所涉及的受体进行表征。平滑肌细胞通过酶消化进行分散。通过测量50个细胞的长度来评估收缩,并表示为细胞长度相对于对照值的减少百分比。PTH、PTHrP及其类似物VIP或拮抗剂的舒张作用表示为在无它们时观察到的最大效应的百分比。VIP、PTH-(1-34)、PTHrP-(1-34)、-(1-16)和-(7-34)单独对这些细胞无作用。然而,当细胞被胆囊收缩素的硫酸化C末端八肽(10 nM)收缩时,VIP、PTH-(1-34)和PTHrP(1-34)以浓度依赖性方式抑制胆囊收缩素的硫酸化C末端八肽诱导的收缩,而PTHrP-(1-16)和-(7-34)无作用。VIP、PTH-(1-34)和PTHrP-(1-34)的半数有效浓度(EC50)值分别为7 nM、20 pM和20 pM。VIP拮抗剂([D-P-Cl-Phe6,Leu17]VIP)抑制VIP、PTH-(1-34)和PTHrP(1-34)诱导的舒张,半数抑制浓度(IC50)值分别为20、500和400 pM。同样,PTH/PTHrP拮抗剂[Tyr34-牛PTH-(7-34)NH2]抑制PTH-(1-34)、PTHrP(1-34)和VIP诱导的舒张,IC50值分别为1、1和90 pM。用生长抑素、N-乙基马来酰亚胺和(R)-对环腺苷-3',5'-单磷酸硫代酯对细胞进行预孵育可抑制PTH-(1-34)、PTHrP(1-34)和VIP诱导的舒张。总之,人PTH和PTHrP通过直接的肌源性效应诱导肠道平滑肌舒张。此效应需要1-34氨基酸序列,并由腺苷酸环化酶和蛋白激酶A的激活介导。PTH、PTHrP和VIP之间的相互作用表明它们可能与其各自的受体发生交叉反应。